A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy

References

• Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative normal-tension Glaucoma study group. Am J Ophthalmol. 1998;126:498–505.
   PubMed Web of Science ®Google Scholar
• International Council of Ophthalmology. Guidelines for glaucoma care. 2016; [cited 2022 Mar 29]. Available from: http://www.icoph.org/downloads/ICOGlaucomaGuidelines.pdf.
   Google Scholar
• Janz NK, Wren PA, Lichter PR, et al. The collaborative initial glaucoma treatment study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108(11):1954–1965.
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120(10):1268–1279.
   PubMed Web of Science ®Google Scholar
• The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS investigators. Am J Ophthalmol. 2000;130:429–440.
   PubMed Web of Science ®Google Scholar
• Holló G, Hommer A, Delivery of Glaucoma Care Committee of the European Glaucoma Society. The status of glaucoma diagnostics and care in Europe in 2015: a European survey. Eur J Ophthalmol. 2016;26(3):216–220.
   PubMedGoogle Scholar
• European Glaucoma Society. Terminology and guidelines for glaucoma 5th Edition. 2020; [cited 2022 Mar 29]. Available from: https://www.eugs.org/eng/egs_guidelines_download.asp.
   Google Scholar
• Tabet R, Stewart WC, Feldman R, et al. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv Ophthalmol. 2008;53(6):S85–S92.
   PubMedGoogle Scholar
• Konstas AG, Labbé A, Katsanos A, et al. The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability. Expert Opin Drug Saf. 2021;20(4):453–466.
   PubMed Web of Science ®Google Scholar
• Holló G, Katsanos A, Boboridis KG, et al. Letter to the editor: ‘topical preservative-free ophthalmic treatments an unmet clinical need’. Expert Opin Drug Deliv. 2021;18(4):527–529.
   PubMed Web of Science ®Google Scholar
• Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012;22(1):5–18.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29(4):382–389.
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418–423.
   PubMed Web of Science ®Google Scholar
• Holló G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15(12):1737–1747.
   PubMed Web of Science ®Google Scholar
• Holló G, Katsanos A, Boboridis KG, et al. Preservative-free prostaglandin analogs and prostaglandin/timolol fixed combinations in the treatment of glaucoma: efficacy, safety and potential advantages. Drugs. 2018;78(1):39–64.
   PubMedGoogle Scholar
• Aguayo Bonniard A, Yeung JY, Chan CC, et al. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016;12(11):1279–1289.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Katsanos A, Athanasopoulos GP, et al. Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients. Expert Opin Pharmacother. 2018;19(18):1981–1988.
   PubMed Web of Science ®Google Scholar
• Holló G, Katsanos A. Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma. Expert Opin Drug Saf. 2015;14(4):609–617.
   PubMed Web of Science ®Google Scholar
• Holló G, Vuorinen J, Tuominen J, et al. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014;31(9):932–944.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Tafluprost/timolol: a review in open-angle glaucoma or ocular hypertension. Drugs. 2015;75(15):1807–1813.
   PubMed Web of Science ®Google Scholar
• Kaarniranta K, Ikaheimo K, Mannermaa E, et al. Pharmacokinetics, efficacy, and safety of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in healthy volunteers: a phase I comparison vs. the corresponding preservative-free monotherapies. Clin Pharmacokinet. 2016;55(4):485–494.
   PubMed Web of Science ®Google Scholar
• Pfeiffer N, Traverso CE, Lorenz K, et al. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. Adv Ther. 2014;31(12):1228–1246.
   PubMed Web of Science ®Google Scholar
• Pillunat LE, Erb C, Ropo A, et al. Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study. Clin Ophthalmol. 2017;11:1051–1064.
   PubMed Web of Science ®Google Scholar
• Bourne RRA, Kaarniranta K, Lorenz K, et al. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study. BMJ Open. 2019;9(4):e024129.
   PubMed Web of Science ®Google Scholar
• Oddone F, Tanga L, Kóthy P, et al. Treatment of open-angle glaucoma and ocular hypertension with Preservative-Free tafluprost/timolol fixed-dose combination therapy: the VISIONARY study. Adv Ther. 2020;37(4):1436–1451.
   PubMed Web of Science ®Google Scholar
• Oddone F, Kirwan J, Lopez-Lopez F, et al. Switching to preservative-free tafluprost/timolol fixed-dose combination in the treatment of open-angle glaucoma or ocular hypertension: subanalysis of data from the VISIONARY study according to baseline monotherapy treatment. Adv Ther. 2022. DOI:https://doi.org/10.1007/s12325-022-02166-6
   Google Scholar